Vanflyta is a cancer medicine used to treat adults who have been newly diagnosed with acute myeloid leukaemia (AML), a cancer of the white blood cells. It is only given to those patients whose cancer cells have a particular change (mutation) known as ITD in the gene for a protein called FLT3\. Vanflyta is used together with cytarabine and anthracycline (other cancer medicines, also called chemotherapy) at induction (start of treatment) . After induction it is used in combination with cytarabine alone (consolidation). It is then used on its own as maintenance therapy. Vanflyta contains the active substance quizartinib.
Therapeutic Indication
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single\-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3\-ITD positive.
Therapeutic Area (MeSH)
ATC Code
L01EX11
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
EMA Name
Vanflyta
Medicine Name
Vanflyta
Aliases
N/ANo risk management plan link.
